There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biomerica Inc (BMRA) and Jazz Pharmaceuticals (JAZZ) with bullish sentiments.
Biomerica Inc (BMRA)
B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Biomerica Inc today and set a price target of $6.25. The company’s shares opened today at $2.47, close to its 52-week low of $2.39.
D’silva observed:
“Biomerica, Inc. (BMRA – Buy, $6.25 PT) filed its 10-Q for F1Q19 (August quarter) on 10/15. The company does not host earnings calls. BMRA’s F1Q19 top-line/EPS/adj. EBITDA came in at $1.3M/($0.05)/($0.4M), compared to our estimates of $1.4M/($0.06)/($0.5M), which, we believe, represent consensus, as well. The slight top-line shortfall was primarily due to weaker sales out of Europe than we modeled. Meanwhile, the slightly stronger bottom line was primarily due to lower R&D than we were modeling, as the company continues to hold expenses in check. We continue to believe new partnerships and BMRA’s product pipeline position the enterprise for growth and share price appreciation in the coming years.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 3.8% and a 37.0% success rate. D’silva covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Imprimis Pharmaceuticals, and Oramed Pharmaceuticals.
The the analyst consensus on Biomerica Inc is currently a Hold rating.
See today’s analyst top recommended stocks >>
Jazz Pharmaceuticals (JAZZ)
B.Riley FBR analyst David Buck reiterated a Buy rating on Jazz Pharmaceuticals on December 14 and set a price target of $190. The company’s shares opened today at $138.49, close to its 52-week low of $130.15.
Buck said:
“We reiterate our Buy rating for Jazz Pharmaceuticals plc (JAZZ) shares and our 12-month price target of $190. We update our model to reflect the positive impact of share repurchase including a $426M purchase of shares in 4Q18 and a new reauthorization for $400M without an expiration date. We suspect that the incremental $426M in share repurchases during 4Q18 were done at a price of $150 per share or possibly much less. Using 61.8M diluted shares for 3Q18, we estimate that JAZZ could have repurchased approximately 4.6% of outstanding shares. We lower our outstanding share base by 3.6% for 4Q18 although we stay with 2018E adjusted EPS of $13.05 on higher spending ahead of launch for Jazz’s new excessive sleepiness drug solriamfetol (Solri) continuing into 2019.”
According to TipRanks.com, Buck is a 1-star analyst with an average return of -1.9% and a 38.8% success rate. Buck covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Supernus Pharmaceuticals, and Amag Pharmaceuticals.
Currently, the analyst consensus on Jazz Pharmaceuticals is a Strong Buy with an average price target of $186.55, a 34.7% upside from current levels. In a report issued on December 11, Oppenheimer also initiated coverage with a Buy rating on the stock with a $180 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
